Silymarin

Metastatic Colorectal Cancer

Tanta UniversityPhase 4 / ApprovedActive

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 65/ 100

Competitive context

839 Active assets in the Metastatic Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
FLUOROURACILUM Washington University School of Medicine	Phase 4	BB
PANITUMUMAB M.D. Anderson Cancer Center	Phase 3	BB
Cetuximab Shanghai Henlius Biotech	Phase 4	BB

View all 50 →

Same molecule, other indications

Silymarin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant

BB

Indicative ·

69 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

57 / 100

peripheral neuropathyDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.